Cardiac protection via metabolic modulation: An emerging role for incretin-based therapies?

Cardiovascular and Hematological Agents in Medicinal Chemistry

Volumn 10, Issue 4, 2012, Pages 319-324

  McCormick, Liam M ^a   Kydd, Anna C ^a   Dutka, David P ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Cardioprotection; Diabetes; Dipeptidyl peptidase 4; Glucagon like peptide 1; Glucose; Heart failure; Incretin; Ischaemia reperfusion; Metabolic modulation; Myocardial metabolism

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; EXENDIN 4; FATTY ACID; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; HEMOGLOBIN A1C; INCRETIN; LIRAGLUTIDE; SITAGLIPTIN;

CORONARY ARTERY DISEASE; ENERGY METABOLISM; GLUCOSE HOMEOSTASIS; HEART EJECTION FRACTION; HEART FAILURE; HEART MUSCLE ISCHEMIA; HEART MUSCLE METABOLISM; HEART PROTECTION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PLEIOTROPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SINGLE DRUG DOSE; STRESS ECHOCARDIOGRAPHY;

ANIMALS; CARDIOTONIC AGENTS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; ENERGY METABOLISM; GLUCAGON-LIKE PEPTIDE 1; HUMANS; INCRETINS; MYOCARDIUM;

EID: 84870256445     PISSN: 18715257     EISSN: 18756182     Source Type: Journal    
DOI: 10.2174/187152512803530360     Document Type: Review

References (66)

1. Kenny, S.J.; Aubert, R.E.; Geiss, L.S. Prevalence and Incidence of Non-Insulin-Dependent Diabetes. In: Diabetes in America; Harris, M.I., Cowie, C.C., Stern, M.P., Boyko, E.J., Reiber, G.E., Bennett, P.H., eds. (National Institutes of Health publication #95-1468). Betheda, Md., National Institutes of Health, 1995, pp. 47-67.
2. King, H.; Aubert, R.E.; Herman, W.H. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care, 1998, 21(9), 1414-1431.
3. Reichard, P.; Nilsson, B.Y.; Rosenqvist, U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N. Engl. J. Med., 1993, 329(5), 304-309.
4. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med., 1993, 329(14), 977-986.
5. Ohkubo, Y.; Kishikawa, H.; Araki, E.; Miyata, T.; Isami, S.; Motoyoshi, S.; Kojima, Y.; Furuyoshi, N.; Schichiri, M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res. Clin. Pract., 1995, 28(2), 103-117.
6. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet, 1998, 352(9131), 854-865.
7. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 1998, 352(9131), 837-853.
8. Skyler, J.S.; Bergenstal, R.; Bonow, R.O.; Buse, J.; Deedwania, P.; Gale, E.A.; Howard, B.V.; Kirkman, M.S.; Kosiborod, M.; Reaven, P.; Sherwin, R.S. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation, 2009, 119(2), 351-357.
9. Kannel, W.B.; McGee, D.L. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care, 1979, 2(2), 120-126.
10. Buse, J.B.; Ginsberg, H.N.; Bakris, G.L.; Clark, N.G.; Costa, F.; Eckel, R.; Fonseca, V.; Gerstein, H.C.; Grundy, S.; Nesto, R.W.; Pignone, M.P.; Plutzky, J.; Porte, D.; Redberg, R.; Stitzel, K.F.; Stone, N.J. Primary prevention of cardiovascular diseases in people with diabetes mellitus: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation, 2007, 115(1), 114-126.
11. Cleveland, J.C. Jr.; Meldrum, D.R.; Cain, B.S.; Banerjee, A.; Harken, A.H. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited. Circulation, 1997, 96(1), 29-32.
12. Inzucchi, S.E.; McGuire, D.K. New drugs for the treatment of diabetes: part II: Incretin-based therapy and beyond. Circulation, 2008, 117(4), 574-584.
13. Szmitko, P.E.; Leiter, L.A.; Verma, S. The incretin system and cardiometabolic disease. Can. J. Cardiol., 2010, 26(2), 87-95.
14. Kreymann, B.; Williams, G.; Ghatei, M.A.; Bloom, S.R. Glucagonlike peptide-1 7-36: a physiological incretin in man. Lancet, 1987, 2(8571), 1300-1304.
15. Brown, J.C.; Dryburgh, J.R.; Ross, S.A.; Dupre, J. Identification and actions of gastric inhibitory polypeptide. Recent Prog. Horm. Res., 1975, 31, 487-532.
16. Herrmann, C.; Goke, R.; Richter, G.; Fehmann, H.C.; Arnold, R.; Goke, B. Glucagon-like peptide-1 and glucose-dependent insulinreleasing polypeptide plasma levels in response to nutrients. Digestion, 1995, 56(2), 117-126.
17. Orskov, C.; Rabenhoj, L.; Wettergren, A.; Kofod, H.; Holst, J.J. Tissue and plasma concentrations of amidated and glycineextended glucagon-like peptide I in humans. Diabetes, 1994, 43(4), 535-539.
18. Deacon, C.F.; Nauck, M.A.; Toft-Nielsen, M.; Pridal, L.; Willms, B.; Holst, J.J. Both subcutaneously and intravenously administered glucagon-like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes, 1995, 44(9), 1126-1131.
19. Creutzfeldt, W.O.; Kleine, N.; Willms, B.; Orskov, C.; Holst, J.J.; Nauck, M.A. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care, 1996, 19(6), 580-586.
20. Yusta, B.; Baggio, L.L.; Estall, J.L.; Koehler, J.A.; Holland, D.P.; Li, H.; Pipeleers, D.; Ling, Z.; Drucker, D.J. GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress. Cell Metab., 2006, 4(5), 391-406.
21. Baggio, L.L.; Drucker, D.J. Biology of incretins: GLP-1 and GIP. Gastroenterology, 2007, 132(6), 2131-2157.
22. Lee, L.; Horowitz, J.; Frenneaux, M. Metabolic manipulation in ischaemic heart disease, a novel approach to treatment. Eur. Heart J., 2004, 25(8), 634-641.
23. Stanley, W.C.; Lopaschuk, G.D.; Hall, J.L.; McCormack, J.G. Regulation of myocardial carbohydrate metabolism under normal and ischaemic conditions. Potential for pharmacological interventions. Cardiovasc. Res., 1997, 33(2), 243-257.
24. Gertz, E.W.; Wisneski, J.A.; Stanley, W.C.; Neese, R.A. Myocardial substrate utilization during exercise in humans. Dual carbon-labeled carbohydrate isotope experiments. J. Clin. Invest., 1988, 82(6), 2017-2025.
25. McNulty, P.H.; Jagasia, D.; Cline, G.W.; Ng, C.K.; Whiting, J.M.; Garg, P.; Shulman, G.I.; Soufer, R. Persistent changes in myocardial glucose metabolism in vivo during reperfusion of a limited-duration coronary occlusion. Circulation, 2000, 101(8), 917-922.
26. Stanley, W.C. Cardiac energetics during ischaemia and the rationale for metabolic interventions. Coron. Artery Dis., 2001, 12(Suppl. 1), S3-S7.
27. Liedtke, A.J. Alterations of carbohydrate and lipid metabolism in the acutely ischemic heart. Prog. Cardiovasc. Dis., 1981, 23(5), 321-336.
28. Heusch, G. Hibernating myocardium. Physiol. Rev., 1998, 78(4), 1055-1085.
29. Depre, C.; Vanoverschelde, J.L.; Taegtmeyer, H. Glucose for the heart. Circulation, 1999, 99(4), 578-588.
30. Lopaschuk, G.D.; Wambolt, R.B.; Barr, R.L. An imbalance between glycolysis and glucose oxidation is a possible explanation for the detrimental effects of high levels of fatty acids during aerobic reperfusion of ischemic hearts. J. Pharmacol. Exp. Ther., 1993, 264(1), 135-144.
31. Davila-Roman, V.G.; Vedala, G.; Herrero, P.; de las Fuentes, L.; Rogers, J.G.; Kelly, D.P.; Gropler, R.L. Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy. J. Am. Coll. Cardiol., 2002, 40(2), 271-277.
32. Neubauer, S. The failing heart--an engine out of fuel. N. Engl. J. Med., 2007, 356(11), 1140-1151.
33. Tuunanen, H.; Engblom, E.; Naum, M.; Scheinin, M.; Nagren, K.; Airaksinen, J.; Nuutila, P.; Iozzo, P.; Ukkonen, H.; Knuuti, J. Decreased myocardial free fatty acid uptake in patients with idiopathic dilated cardiomyopathy: evidence of relationship with insulin resistance and left ventricular dysfunction. J. Card. Fail., 2006, 12(8), 644-652.
34. An, D.; Rodrigues, B. Role of changes in cardiac metabolism in development of diabetic cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol., 2006, 291(4), H1489-H1506.
35. Witteles, R.M.; Fowler, M.B. Insulin-resistant cardiomyopathy clinical evidence, mechanisms, and treatment options. J. Am. Coll. Cardiol., 2008, 51(2), 93-102.
36. Ban, K.; Noyan-Ashraf, M.H.; Hoefer, J.; Bolz, S.S.; Drucker, D.J.; Husain, M. Cardioprotective and vasodilatory actions of glucagonlike peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation, 2008, 117(18), 2340-2350.
37. Mudaliar, S.; Henry, R.R. Incretin therapies: effects beyond glycemic control. Am. J. Med., 2009, 122(6 Suppl), S25-S36.
38. Bose, A.K.; Mocanu, M.M.; Carr, R.D.; Yellon, D.M. Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model. Cardiovasc. Drugs Ther., 2005, 19(1), 9-11.
39. Bose, A.K.; Mocanu, M.M.; Carr, R.D.; Brand, C.L.; Yellon, D.M. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes, 2005, 54(1), 146-151.
40. Sonne, D.P.; Engstrom, T.; Treiman, M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemiareperfusion injury in rat heart. Regul. Pept., 2008, 146(1-3), 243-249.
41. Zhao, T.; Parikh, P.; Bhashyam, S.; Bolukoglu, H.; Poornima, I.; Shen, Y.T.; Shannon, R.P. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J. Pharmacol. Exp. Ther., 2006, 317(3), 1106-1113.
42. Timmers, L.; Henriques, J.P.; de Kleijn, D.P.; Devries, J.H.; Kemperman, H.; Steendijk, P.; Verlaan, C.W.; Kerver, M.; Piek, J.J.; Doevendans, P.A.; Pasterkamp, G.; Hoefer, I.E. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J. Am. Coll. Cardiol., 2009, 53(6), 501-510.
43. Noyan-Ashraf, M.H.; Momen, MA.; Ban, K.; Sadi, A.M.; Zhou, Y.Q.; Riazi, A.M.; Baggio, L.L.; Henkelman, R.M.; Husain, M.; Drucker, D.J. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes, 2009, 58(4), 975-983.
44. Nikolaidis, L.A.; Doverspike, A.; Hentosz, T.; Zourelias, L.; Shen, Y.T.; Elahi, D.; Shannon, R.P. Glucagon-like peptide-1 limits myocardial stunning following brief coronary occlusion and reperfusion in conscious canines. J. Pharmacol. Exp. Ther., 2005, 312(1), 303-308.
45. Kristensen, J.; Mortensen, U.M.; Schmidt, M.; Nielsen, P.H.; Nielsen, T.T.; Maeng, M. Lack of cardioprotection from subcutaneously and preischemic administered liraglutide in a closed chest porcine ischemia reperfusion model. BMC Cardiovasc. Disord., 2009, 9, 31.
46. Kavianipour, M.; Ehlers, M.R.; Malmberg, K.; Ronquist, G.; Ryden, L.; Wikstrom, G.; Gutniak, M. Glucagon-like peptide-1 (7-36) amide prevents the accumulation of pyruvate and lactate in the ischemic and non-ischemic porcine myocardium. Peptides, 2003, 24(4), 569-578.
47. Bao, W.; Aravindhan, K.; Chendrmada, T.; Szapacs, M.; Citerone, D.R.; Harpel, M.R.; Willette, R.N.; Lepore, J.J.; Jucker, B.M. Albiglutide, a long lasting glucagon-like peptide-1 analog, protects the rat heart against ischemia/reperfusion injury: evidence for improving cardiac metabolic efficiency. PLoS One, 2011, 6(8), e23570.
48. Nikolaidis, L.A.; Elahi, D.; Shen, Y.T.; Shannon, R.P. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol., 2005, 289(6), H2401-H2408.
49. Nikolaidis, L.A.; Elahi, D.; Hentosz, T.; Doverspike, A.; Huerbin, R.; Zourelias, L.; Stolarski, C.; Shen, Y.T.; Shannon, R.P. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation, 2004, 110(8), 955-961.
50. Read, P.A.; Hoole, S.P.; White, P.A.; Khan, F.Z.; O'Sullivan, M.; West, N.E.; Dutka, D.P. A pilot study to assess whether glucagonlike peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans. Circ. Cardiovasc. Interv., 2011, 4(3), 266-272.
51. Read, P.A.; Khan, F.Z.; Dutka, D.P. Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease. Heart, 2012, 98(5), 408-413.
52. Read, P.A.; Khan, F.Z.; Heck, P.M.; Hoole, S.P.; Dutka, D.P. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease. Circ. Cardiovasc. Imaging, 2010, 3(2), 195-201.
53. Sokos, G.G.; Bolukoglu, H.; Hentosz, T.; Magovern, G. J. Jr.; Maher, T.D.; Dean, D.A.; Bailey, S.H.; Marrone, G.; Benckart, D.H.; Elahi, D.; Shannon, R.P. Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting. Am. J. Cardiol., 2007, 100(5), 824-829.
54. Mussig, K.; Oncu, A.; Lindauer, P.; Heininger, A.; Aebert, H.; Unertl, K.; Ziemer, G.; Haring, H.U.; Holst, J.J.; Gallwitz, B. Effects of intravenous glucagon-like peptide-1 on glucose control and hemodynamics after coronary artery bypass surgery in patients with type 2 diabetes. Am. J. Cardiol., 2008, 102(5), 646-647.
55. Nikolaidis, L.A.; Mankad, S.; Sokos, G.G.; Miske, G.; Shah, A.; Elahi, D.; Shannon, R.P. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation, 2004, 109(8), 962-965.
56. Lonborg, J.; Vejlstrup, N.; Kelbaek, H.; Botker, H.E.; Kim, W.Y.; Mathiasen, A.B.; Jorgensen, E.; Helqvist, S.; Saunamaki, K.; Clemmensen, P.; Holmvang, L.; Thuesen, L.; Krusell, L.R.; Jensen, J.S.; Kober, L.; Treiman, M.; Holst, J.J.; Engstrom, T. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur. Heart J., 2012, 33(12), 1491-1499.
57. Poornima, I.; Brown, S.B.; Bhashyam, S.; Parikh, P.; Bolukoglu, H.; Shannon, R.P. Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. Circ. Heart Fail., 2008, 1(3), 153-160.
58. Thrainsdottir, I.; Malmberg, K.; Olsson, A.; Gutniak, M.; Ryden, L. Initial experience with GLP-1 treatment on metabolic control and myocardial function in patients with type 2 diabetes mellitus and heart failure. Diab. Vasc. Dis. Res., 2004, 1(1), 40-43.
59. Sokos, G.G.; Nikolaidis, L.A.; Mankad, S.; Elahi, D.; Shannon, R.P. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J. Card. Fail., 2006, 12(9), 694-699.
60. Halbirk, M.; Norrelund, H.; Moller, N.; Holst, J.J.; Schmitz, O.; Nielsen, R.; Nielsen-Kudsk, J.E.; Nielsen, S.S.; Nielsen, T.T.; Eiskjaer, H.; Botker, H.E.; Wiggers, H. Cardiovascular and metabolic effects of 48-h glucagon-like peptide-1 infusion in compensated chronic patients with heart failure. Am. J. Physiol. Heart Circ. Physiol., 2010, 298(3), H1096-H1102.
61. Wei, Y.; Mojsov, S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett., 1995, 358(3), 219-224.
62. Bullock, B.P.; Heller, R.S.; Habener, J.F. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology, 1996, 137(7), 2968-2978.
63. Gros, R.; You, X.; Baggio, L.L.; Kabir, M.G.; Sadi, A.M.; Mungrue, I.N.; Parker, T.G.; Huang, Q.; Drucker, D.J.; Husain, M. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology, 2003, 144(6), 2242-2252.
64. Okerson, T.; Chilton, R.J. The Cardiovascular Effects of GLP-1 Receptor Agonists. Cardiovasc. Ther., 2012, 30(3), e146-e155.
65. Abu-Hamdah, R.; Rabiee, A.; Meneilly, G.S.; Shannon, R.P.; Andersen, D.K.; Elahi, D. Clinical review: The extrapancreatic effects of glucagon-like peptide-1 and related peptides. J. Clin. Endocrinol. Metab., 2009, 94(6), 1843-1852.
66. Grieve, D.J.; Cassidy, R.S.; Green, B.D. Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control? Br. J. Pharmacol., 2009, 157(8), 1340-1351.